WHO ICTRP trial
Efficacy and Safety of Ustekinumab Biosimilar in Patients with Psoriasis…
JPRN-jRCTs041240172 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs041240172 |
|---|---|
| Public title | Efficacy and Safety of Ustekinumab Biosimilar in Patients with Psoriasis Vulgaris |
| Scientific title | Efficacy and Safety of Ustekinumab Biosimilar in Patients with Psoriasis Vulgaris |
| Primary sponsor | Morita Akimichi |
| Secondary sponsors | Miyachi Yoshiki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Conditions | Psoriasis vulgaris psoriasis;C17.800.859.675;psoriasis |
| Interventions | 1)Patients with Psoriasis vulgaris undergoing treatment with biologicals. (1) Treatment start (0 week) - End of treatment a-1. Patients undergoing treatment with Stelara. Continuation of the dose at enrollment, the study drug (ustekinumab… |
| Registration date | Jan 22, 2025 |
| Target size | 50 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: